A review on pharmacological and clinical studies of deucravacitinib
Deucravacitinib is the first-in-class oral selective tyrosine kinase 2(TYK2)inhibitor.It is widely investigated in clinical trials for the treatment of autoimmune and chronic inflammatory diseases.In this review,we aim to highlight the mechanism,discovery history,clinical evaluation,and research progress of drugs also targeting at TYK2.
deucravacitinibselective tyrosine kinase 2 inhibitorautoimmune and chronic inflammatory diseasespsoriasis
NETL
NSTL
万方数据
维普
